Logo image of EIGR

EIGER BIOPHARMACEUTICALS INC (EIGR) Stock Fundamental Analysis

NASDAQ:EIGR - Nasdaq - US28249U2042 - Common Stock - Currency: USD

1.725  -0.17 (-9.21%)

After market: 1.7 -0.03 (-1.45%)

Fundamental Rating

2

EIGR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of EIGR have multiple concerns. EIGR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EIGR had negative earnings in the past year.
In the past year EIGR has reported a negative cash flow from operations.
EIGR had negative earnings in each of the past 5 years.
EIGR had a negative operating cash flow in each of the past 5 years.
EIGR Yearly Net Income VS EBIT VS OCF VS FCFEIGR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

EIGR has a worse Return On Assets (-193.08%) than 89.08% of its industry peers.
Industry RankSector Rank
ROA -193.08%
ROE N/A
ROIC N/A
ROA(3y)-100.16%
ROA(5y)-82.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EIGR Yearly ROA, ROE, ROICEIGR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

EIGR has a Gross Margin of 99.87%. This is amongst the best in the industry. EIGR outperforms 99.32% of its industry peers.
EIGR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EIGR Yearly Profit, Operating, Gross MarginsEIGR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

EIGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EIGR has less shares outstanding
Compared to 5 years ago, EIGR has less shares outstanding
The debt/assets ratio for EIGR is higher compared to a year ago.
EIGR Yearly Shares OutstandingEIGR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
EIGR Yearly Total Debt VS Total AssetsEIGR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

EIGR has an Altman-Z score of -24.61. This is a bad value and indicates that EIGR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -24.61, EIGR is doing worse than 88.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -24.61
ROIC/WACCN/A
WACC7.86%
EIGR Yearly LT Debt VS Equity VS FCFEIGR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.71 indicates that EIGR may have some problems paying its short term obligations.
EIGR's Current ratio of 0.71 is on the low side compared to the rest of the industry. EIGR is outperformed by 93.52% of its industry peers.
A Quick Ratio of 0.68 indicates that EIGR may have some problems paying its short term obligations.
EIGR has a Quick ratio of 0.68. This is amonst the worse of the industry: EIGR underperforms 92.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.68
EIGR Yearly Current Assets VS Current LiabilitesEIGR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for EIGR have decreased strongly by -348.44% in the last year.
EIGR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.01%.
EPS 1Y (TTM)-348.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1495.35%
Revenue 1Y (TTM)17.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.85%

3.2 Future

The Earnings Per Share is expected to grow by 14.90% on average over the next years. This is quite good.
The Revenue is expected to grow by 24.85% on average over the next years. This is a very strong growth
EPS Next Y68.29%
EPS Next 2Y38.81%
EPS Next 3Y25.95%
EPS Next 5Y14.9%
Revenue Next Year37.05%
Revenue Next 2Y33.22%
Revenue Next 3Y23.14%
Revenue Next 5Y24.85%

3.3 Evolution

EIGR Yearly Revenue VS EstimatesEIGR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
EIGR Yearly EPS VS EstimatesEIGR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EIGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EIGR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EIGR Price Earnings VS Forward Price EarningsEIGR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EIGR Per share dataEIGR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as EIGR's earnings are expected to grow with 25.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.81%
EPS Next 3Y25.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EIGR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EIGER BIOPHARMACEUTICALS INC

NASDAQ:EIGR (4/10/2024, 8:00:01 PM)

After market: 1.7 -0.03 (-1.45%)

1.725

-0.17 (-9.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11 2023-05-11/amc
Earnings (Next)N/A N/A
Inst Owners2.19%
Inst Owner Change0%
Ins Owners241.77%
Ins Owner Change0%
Market Cap2.55M
Analysts87.5
Price Target91.8 (5221.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-39.22%
Min Revenue beat(2)-42.46%
Max Revenue beat(2)-35.98%
Revenue beat(4)0
Avg Revenue beat(4)-20.45%
Min Revenue beat(4)-42.46%
Max Revenue beat(4)-0.43%
Revenue beat(8)0
Avg Revenue beat(8)-22.41%
Revenue beat(12)1
Avg Revenue beat(12)-21.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-159.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-2900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.16
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.49
EYN/A
EPS(NY)-15.91
Fwd EYN/A
FCF(TTM)-50.55
FCFYN/A
OCF(TTM)-50.39
OCFYN/A
SpS10.66
BVpS-9.77
TBVpS-9.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -193.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.87%
FCFM N/A
ROA(3y)-100.16%
ROA(5y)-82.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.09%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.68
Altman-Z -24.61
F-Score4
WACC7.86%
ROIC/WACCN/A
Cap/Depr(3y)94.83%
Cap/Depr(5y)224.63%
Cap/Sales(3y)1.97%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-348.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1495.35%
EPS Next Y68.29%
EPS Next 2Y38.81%
EPS Next 3Y25.95%
EPS Next 5Y14.9%
Revenue 1Y (TTM)17.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.85%
Revenue Next Year37.05%
Revenue Next 2Y33.22%
Revenue Next 3Y23.14%
Revenue Next 5Y24.85%
EBIT growth 1Y22.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year107.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.19%
OCF growth 3YN/A
OCF growth 5YN/A